Research Division, Chugai Pharmaceutical Co, Ltd, Gotemba, Japan.
Chugai Pharmabody Research Pte. Ltd, Singapore.
MAbs. 2022 Jan-Dec;14(1):2068213. doi: 10.1080/19420862.2022.2068213.
A conventional antibody targeting a soluble antigen in circulation typically requires a huge dosage and frequent intravenous administration to neutralize the antigen. This is because antigen degradation is reduced by the formation of antigen-antibody immune complexes, which escape from lysosomal degradation using neonatal Fc receptor (FcRn)-mediated recycling. To address this, we developed an antigen-sweeping antibody that combines pH-dependent antigen binding and Fc engineering to enhance Fc receptor binding. The sweeping antibody actively eliminates the plasma antigens by increasing the cellular uptake of the immune complex and dissociating the antigens in the acidic endosome for degradation. Strong antigen sweeping can reduce the dosage, potentially achieve higher efficacy, and expand the scope of antigen space available for targeting by antibodies. In this study, to further improve the sweeping efficacy, we developed a novel antibody Fc variant by enhancing Fcγ receptor IIb (FcγRIIb) binding and modulating charge characteristics for increased cellular uptake of the immune complex, together with enhancing FcRn binding for efficient salvage of the antigen-free antibodies. Our Fc variant achieved strong antigen sweeping in cynomolgus monkeys with antibody pharmacokinetics comparable to a wild-type human IgG antibody. The positive-charge substitutions enhanced uptake of the immune complex by FcγRIIb-expressing cells in vitro, which was completely inhibited by an anti-FcγRIIb antibody. This suggests that the strong in vivo sweeping efficacy improved by the charge engineering is more likely achieved by FcγRIIb-dependent uptake of the immune complex rather than nonspecific uptake. We expect this novel Fc engineering can maximize the antigen sweeping efficacy even in humans and create novel therapeutic antibodies that meet unmet medical needs for patients.
传统的针对循环中可溶性抗原的抗体通常需要大剂量和频繁的静脉内给药才能中和抗原。这是因为抗原降解会因抗原抗体免疫复合物的形成而减少,这些复合物通过新生儿 Fc 受体 (FcRn) 介导的循环利用从溶酶体降解中逃脱。为了解决这个问题,我们开发了一种抗原清扫抗体,它结合了 pH 依赖性抗原结合和 Fc 工程,以增强 Fc 受体结合。清扫抗体通过增加免疫复合物的细胞摄取并在酸性内体中解离抗原以进行降解,从而主动消除血浆抗原。强烈的抗原清扫可以减少剂量,有可能实现更高的疗效,并扩大抗体可靶向的抗原空间范围。在这项研究中,为了进一步提高清扫效果,我们通过增强 Fcγ 受体 IIb (FcγRIIb) 结合和调节电荷特性来开发一种新型抗体 Fc 变体,以增加免疫复合物的细胞摄取,同时增强 FcRn 结合以有效回收无抗原的抗体。我们的 Fc 变体在食蟹猴中实现了强烈的抗原清扫,其抗体药代动力学与野生型人 IgG 抗体相当。正电荷取代增强了 FcγRIIb 表达细胞对免疫复合物的摄取,这一摄取可被抗 FcγRIIb 抗体完全抑制。这表明电荷工程增强的体内清扫效果更可能是通过 FcγRIIb 依赖性摄取免疫复合物而不是非特异性摄取来实现的。我们期望这种新型 Fc 工程能够最大限度地提高抗原清扫效果,即使在人类中也是如此,并创造出满足患者未满足医疗需求的新型治疗性抗体。